The FDA Just Open-Sourced Drug Failure Data. Sell the Taxonomy Back to Wall Street.
The FDA published hundreds of drug rejection letters in 2025 — a new public dataset ripe for a niche B2B SaaS play in regulatory intelligence and biotech delay risk analytics